Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada
12.07.2026 03:19
Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...
If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now
10.07.2026 12:30
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?
10.07.2026 12:14
With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.
The Long Climb Back For Ionis Stock
10.07.2026 11:35
A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.
1 Momentum Stock to Research Further and 2 Facing Headwinds
09.07.2026 07:49
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?
09.07.2026 03:39
Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?
08.07.2026 05:11
Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today?
08.07.2026 03:34
Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits.
Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout
08.07.2026 03:09
Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?
Top Midday Stories: Amazon Seeking at Least $25 Billion From US Bond Sale; Fiserv Explores Sale of STAR Debit Network
07.07.2026 15:43
All three major US stock indexes were down in late-morning trading Tuesday, with the Nasdaq Composit
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
07.07.2026 14:56
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.
Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock
07.07.2026 13:59
H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar.
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
07.07.2026 13:26
Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.
Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets
07.07.2026 12:24
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash). Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing. Vertex’s cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion. Read Also: Ver
Vertex Pharmaceuticals buying Crinetics for $10 billion
07.07.2026 12:14
The deal gives Vertex access to Palsonify, an oral acromegaly treatment, and atumelnant, a late-stage drug for congenital adrenal hyperplasia
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal
07.07.2026 11:33
Crinetics Pharmaceuticals stock was surging on Tuesday after Vertex Pharmaceuticals said it had agreed to buy the biotech for $10 billion. Vertex slid 1.2%. Vertex said in a press release late Monday that it would buy Crinetics, which specializes in discovering and developing treatments for endocrine diseases, for $85 a share in cash.
Vertex Pharmaceuticals to Buy Crinetics in $10 Billion Deal
07.07.2026 11:06
Vertex Pharmaceuticals (VRTX) agreed to acquire endocrine disease drugmaker Crinetics Pharmaceutical
Vertex signs agreement to acquire Crinetics for $10bn
07.07.2026 10:55
The acquisition is expected to close in the third quarter of 2026.
Crinetics (CRNX) Stock Could Be Overvalued After Its 113% Run
07.07.2026 10:17
Crinetics Pharmaceuticals stock has delivered a strong 112.8% return over the past three years, yet its valuation checks paint a mixed picture at the same time as investors weigh the agreed US$85 per share cash acquisition by Vertex Pharmaceuticals against the current market pricing. Over the last three years, Crinetics Pharmaceuticals has returned 112.8%, which puts recent gains in the context of a longer period of substantial shareholder returns. Vertex's planned US$10b cash acquisition,...
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
07.07.2026 09:39
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.